Assertio Therapeutics
ASRTUnlisted companyAbout Assertio Therapeutics
Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Assertio Therapeutics timeline
- 1995
- 🏁· approximateFounded
- 2018
- 📉· approximateDelisted from Nasdaq
Events of Assertio Therapeutics from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Assertio Therapeutics
- Acquisitions and changes
- No longer listed: ticker ASRT is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #3,695 (Jan 2020) · #4,183 (Jan 2021) · #4,246 (Jan 2022) · #3,683 (Dec 2022) · #3,138 (Jul 2023) · #3,722 (Jan 2024) · #2,026 (Mar 2026)
Mutual funds holding Assertio Therapeutics#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 33,898 | $1 M | — | <0.01% | +1.8% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 11,355 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 9,478 | $0 M | — | <0.01% | +10% | May 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 3,885 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,360 | $0 M | — | <0.01% | +22% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: Assertio Therapeutics#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-06-15 23:50 UTC, code D, resumed 04:00 UTC
- 2026-05-13 11:55 UTC, code T3, resumed 12:20 UTC
- 2025-12-24 21:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 1,890 shares at $23.50
- : 19 shares at $23.47
- : 19 shares at $23.48
- : 52,403 shares at $23.44
- : 3,878 shares at $23.47
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lobbying by Assertio Therapeutics#
$0 spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2025
Farragut Partners LLP
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2025 | $0 | — | 1 |
| 2024 | $200 K | — | 4 |
| 2023 | $100 K | — | 2 |
| 2019 | $200 K | — | 4 |
| 2018 | $70 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Assertio Holdings, Inc” and “Assertio Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Assertio Therapeutics🇺🇸 | $75 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Mar 8, 2026 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research, Wikipedia.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Assertio Therapeutics? Verify and update this profile — free
Show Assertio Therapeutics's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.